ANIP - ANI Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Baudette,
United States
Type: Equity
ANIP price evolution
ANIP
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $240.11 | $228.6 | $221.12 | |
| Short term investments | $6.94 | $9.65 | ||
| Net receivables | $202.47 | $168.96 | $172.42 | $162.08 |
| Inventory | $148.04 | $125.45 | $113.84 | $111.2 |
| Total current assets | $521.3 | $555.46 | $540.56 | $519.82 |
| Long term investments | ||||
| Property, plant & equipment | $56.7 | $51.64 | $48.53 | $44.59 |
| Goodwill & intangible assets | $211.3 | $224.26 | $237.23 | |
| Total noncurrent assets | $365.29 | $373.97 | $384.61 | |
| Total investments | $6.94 | $9.65 | ||
| Total assets | $1287.38 | $920.75 | $914.52 | $904.42 |
| Current liabilities | ||||
| Accounts payable | $60.89 | $48.68 | $49.43 | $36.68 |
| Deferred revenue | ||||
| Short long term debt | $0.85 | $0.85 | $0.85 | |
| Total current liabilities | $189.93 | $139.98 | $136.89 | $145.48 |
| Long term debt | $618.21 | $284.39 | $284.61 | $284.82 |
| Total noncurrent liabilities | $300.17 | $300.82 | $301.35 | |
| Total debt | $285.24 | $285.46 | $285.67 | |
| Total liabilities | $856.58 | $440.14 | $437.71 | $446.82 |
| Shareholders' equity | ||||
| Retained earnings | -$89.6 | -$65.03 | -$62.33 | -$80.13 |
| Other shareholder equity | $5.37 | $8.33 | $9.41 | $8.86 |
| Total shareholder equity | $455.76 | $451.96 | $432.75 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $221.12 | $53.23 | $105.3 | $12.87 |
| Short term investments | ||||
| Net receivables | $162.08 | $169.26 | $128.53 | $95.79 |
| Inventory | $111.2 | $105.36 | $81.69 | $60.8 |
| Total current assets | $519.82 | $344.26 | $321.77 | $170.32 |
| Long term investments | ||||
| Property, plant & equipment | $44.59 | $43.25 | $52.67 | $41.27 |
| Goodwill & intangible assets | $237.23 | $279.86 | $322.01 | $192.09 |
| Total noncurrent assets | $384.61 | $415.83 | $449.82 | $290.87 |
| Total investments | ||||
| Total assets | $904.42 | $760.09 | $771.6 | $461.19 |
| Current liabilities | ||||
| Accounts payable | $36.68 | $29.3 | $22.97 | $11.26 |
| Deferred revenue | $0.09 | $0.08 | ||
| Short long term debt | $0.85 | $0.85 | $0.85 | $13.24 |
| Total current liabilities | $145.48 | $99.44 | $87.54 | $78.56 |
| Long term debt | $284.82 | $285.67 | $286.52 | $172.44 |
| Total noncurrent liabilities | $301.35 | $322.11 | $325.32 | $186.93 |
| Total debt | $285.67 | $286.52 | $287.37 | $185.69 |
| Total liabilities | $446.82 | $421.55 | $412.86 | $265.49 |
| Shareholders' equity | ||||
| Retained earnings | -$80.13 | -$97.29 | -$47.77 | -$4.97 |
| Other shareholder equity | $8.86 | $12.17 | -$3.06 | -$11.44 |
| Total shareholder equity | $432.75 | $313.69 | $333.89 | $195.7 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $137.43 | $131.65 | ||
| Cost of revenue | $49.16 | $53.42 | ||
| Gross Profit | $88.27 | $78.23 | ||
| Operating activities | ||||
| Research & development | $10.51 | $9.87 | ||
| Selling, general & administrative | $48.02 | $44.46 | ||
| Total operating expenses | $67.87 | $69.56 | ||
| Operating income | $20.4 | $8.68 | ||
| Income from continuing operations | ||||
| EBIT | $29.93 | $6.69 | ||
| Income tax expense | $7.13 | -$0.21 | ||
| Interest expense | $4.6 | $5.75 | ||
| Net income | ||||
| Net income | $18.21 | $1.16 | ||
| Income (for common shares) | $17.8 | $0.75 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $486.82 | $316.38 | $216.14 | $208.47 |
| Cost of revenue | $181.51 | $138.78 | $100.61 | $87.16 |
| Gross Profit | $305.3 | $177.6 | $115.53 | $121.32 |
| Operating activities | ||||
| Research & development | $34.29 | $22.32 | $11.37 | $16 |
| Selling, general & administrative | $161.7 | $124.04 | $84.29 | $64.99 |
| Total operating expenses | $257.06 | $208.46 | $159.16 | $137.83 |
| Operating income | $48.24 | -$30.86 | -$43.64 | -$16.51 |
| Income from continuing operations | ||||
| EBIT | $46.81 | -$34.61 | -$44.14 | -$16.51 |
| Income tax expense | $1.09 | -$14.77 | -$13.46 | -$3.41 |
| Interest expense | $26.94 | $28.05 | $11.92 | $9.45 |
| Net income | ||||
| Net income | $18.78 | -$47.9 | -$42.6 | -$22.55 |
| Income (for common shares) | $17.15 | -$49.52 | -$42.79 | -$22.55 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$2.29 | $18.21 | $1.16 | |
| Operating activities | ||||
| Depreciation | $15.07 | $15.06 | $15.57 | |
| Business acquisitions & disposals | -$2.5 | |||
| Stock-based compensation | $7.86 | $6.93 | $5.62 | |
| Total cash flows from operations | $17.41 | $18.27 | $44.74 | |
| Investing activities | ||||
| Capital expenditures | -$4.45 | $8.93 | -$2.28 | |
| Investments | ||||
| Total cash flows from investing | -$394.04 | -$4.45 | $8.93 | -$4.78 |
| Financing activities | ||||
| Dividends paid | -$1.22 | |||
| Sale and purchase of stock | -$0.29 | -$6.07 | $1.74 | |
| Net borrowings | -$0.75 | -$0.75 | -$0.75 | |
| Total cash flows from financing | $269.85 | -$1.45 | -$19.73 | -$11.92 |
| Effect of exchange rate | -$0.07 | |||
| Change in cash and equivalents | -$76.1 | $11.51 | $7.48 | $28.04 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $18.78 | -$47.9 | -$42.6 | -$22.55 |
| Operating activities | ||||
| Depreciation | $61.06 | $59.65 | $47.25 | $44.64 |
| Business acquisitions & disposals | -$9.64 | -$7.61 | -$105.58 | -$62.19 |
| Stock-based compensation | $20.65 | $14.6 | $10.49 | $12.94 |
| Total cash flows from operations | $118.96 | -$31.2 | $3.32 | $15.27 |
| Investing activities | ||||
| Capital expenditures | -$8.87 | -$8.13 | $0.09 | -$6.13 |
| Investments | ||||
| Total cash flows from investing | -$18.51 | -$15.74 | -$105.48 | -$68.32 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $84.56 | -$0.5 | $76.18 | -$0.91 |
| Net borrowings | -$3 | -$3 | $99.02 | -$0.53 |
| Total cash flows from financing | $67.44 | -$5.13 | $194.59 | -$1.44 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $167.89 | -$52.07 | $92.43 | -$54.49 |
News
Fundamentals
| Market cap | $1.24B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 21.08M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.03 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.74 |
| Quick ratio | 1.97 |